Murray D. Norris

13.6k total citations · 2 hit papers
197 papers, 8.2k citations indexed

About

Murray D. Norris is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Murray D. Norris has authored 197 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Molecular Biology, 93 papers in Neurology and 48 papers in Oncology. Recurrent topics in Murray D. Norris's work include Neuroblastoma Research and Treatments (93 papers), Acute Lymphoblastic Leukemia research (42 papers) and Cancer therapeutics and mechanisms (39 papers). Murray D. Norris is often cited by papers focused on Neuroblastoma Research and Treatments (93 papers), Acute Lymphoblastic Leukemia research (42 papers) and Cancer therapeutics and mechanisms (39 papers). Murray D. Norris collaborates with scholars based in Australia, United States and Italy. Murray D. Norris's co-authors include Michelle Haber, Michelle J. Henderson, Glenn M. Marshall, Jamie I. Fletcher, Maria Kavallaris, Catherine A. Burkhart, Susan Band Horwitz, Janice Madafiglio, Susan L. Cohn and Belamy B. Cheung and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Murray D. Norris

193 papers receiving 8.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABC transporters in cancer: more than just drug efflux pumps

2010 833 citations Jamie I. Fletcher, Michelle Haber et al. profile →
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

1997 502 citations Maria Kavallaris, Catherine A. Burkhart et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Murray D. Norris	4.8k	3.1k	1.8k	1.6k	826	197	8.2k
Richard B. Lock	5.1k 1.1×	2.8k 0.9×	1.0k 0.6×	1.2k 0.8×	1.5k 1.9×	260	8.7k
Marcel Kool	8.2k 1.7×	5.5k 1.8×	1.1k 0.6×	1.7k 1.1×	623 0.8×	215	14.4k
Raymond Lai	4.7k 1.0×	4.8k 1.5×	477 0.3×	1.6k 1.0×	337 0.4×	262	11.1k
Gerard P. Zambetti	10.6k 2.2×	8.0k 2.6×	664 0.4×	3.2k 2.0×	256 0.3×	133	15.7k
Marian H. Harris	6.8k 1.4×	1.6k 0.5×	297 0.2×	4.2k 2.6×	640 0.8×	78	11.1k
Wael El‐Rifai	5.3k 1.1×	2.6k 0.8×	426 0.2×	2.3k 1.5×	141 0.2×	209	10.4k
Maxwell Sehested	6.7k 1.4×	4.4k 1.4×	297 0.2×	1.4k 0.9×	195 0.2×	154	9.9k
Ralf C. Bargou	4.7k 1.0×	6.4k 2.1×	373 0.2×	918 0.6×	1.9k 2.3×	178	11.7k
Yoshitaka Sekido	9.3k 1.9×	3.7k 1.2×	370 0.2×	3.3k 2.1×	191 0.2×	199	14.3k
Victoria M. Richon	20.3k 4.2×	5.2k 1.7×	513 0.3×	1.4k 0.9×	473 0.6×	123	23.0k

Countries citing papers authored by Murray D. Norris

Since Specialization

Citations

This map shows the geographic impact of Murray D. Norris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murray D. Norris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murray D. Norris more than expected).

Fields of papers citing papers by Murray D. Norris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murray D. Norris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murray D. Norris. The network helps show where Murray D. Norris may publish in the future.

Co-authorship network of co-authors of Murray D. Norris

This figure shows the co-authorship network connecting the top 25 collaborators of Murray D. Norris. A scholar is included among the top collaborators of Murray D. Norris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murray D. Norris. Murray D. Norris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atkinson, Caroline, Alvin Kamili, Federica Saletta, et al.. (2025). P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma. SHILAP Revista de lepidopterología. 6. 100478–100478.

Khan, Aaminah, Laura D. Gamble, Dannielle Upton, et al.. (2021). Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. Nature Communications. 12(1). 971–971. 84 indexed citations

Zhong, Ling, Chelsea Mayoh, Murray D. Norris, et al.. (2020). Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2 -Rearranged Ph-like ALL. Molecular Cancer Research. 18(12). 1767–1776. 2 indexed citations

Gao, Jixuan, MoonSun Jung, Chelsea Mayoh, et al.. (2020). Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression. Cancer Research. 80(17). 3706–3718. 18 indexed citations

Kamili, Alvin, Andrew J. Gifford, Nancy Li, et al.. (2020). Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. British Journal of Cancer. 122(5). 680–691. 32 indexed citations

Hanssen, Kimberley M., Denise Yu, Claudia L. Flemming, et al.. (2019). MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology. 168. 237–248. 36 indexed citations

Carter, Daniel R., Bing Liu, Chelsea Mayoh, et al.. (2018). Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. Cancer Research. 78(12). 3122–3134. 45 indexed citations

Evageliou, Nicholas F., Michelle Haber, Annette Vu, et al.. (2016). Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clinical Cancer Research. 22(17). 4391–4404. 64 indexed citations

Tran, Sieu L., Michelle F. Maritz, Bing Liu, et al.. (2016). MYC -Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. Cancer Research. 76(12). 3604–3617. 36 indexed citations

10.

Jung, MoonSun, Amanda J. Russell, Bing Liu, et al.. (2016). A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research. 77(4). 971–981. 75 indexed citations

11.

Tan, Owen, Bing Liu, Toby N. Trahair, et al.. (2016). High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. Cancer Letters. 374(2). 315–323. 48 indexed citations

12.

Greenop, Kathryn R., Rodney J. Scott, John Attia, et al.. (2015). Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study. Cancer Epidemiology Biomarkers & Prevention. 24(6). 931–937. 6 indexed citations

13.

Yu, Denise, et al.. (2015). ABC Transporters and Neuroblastoma. Advances in cancer research. 125. 139–170. 28 indexed citations

14.

Milne, Elizabeth, Kathryn R. Greenop, Rodney J. Scott, et al.. (2014). Folate Pathway Gene Polymorphisms, Maternal Folic Acid Use, and Risk of Childhood Acute Lymphoblastic Leukemia. Cancer Epidemiology Biomarkers & Prevention. 24(1). 48–56. 15 indexed citations

15.

Pasquier, Eddy, Janine Street, Manon Carré, et al.. (2013). β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. British Journal of Cancer. 108(12). 2485–2494. 126 indexed citations

16.

Hesson, Luke B., et al.. (2012). Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma. Clinical Cancer Research. 18(20). 5690–5700. 22 indexed citations

17.

Fletcher, Jamie I., Samuele Gherardi, Jayne Murray, et al.. (2011). N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1 , a Marker of Poor Outcome in Neuroblastoma. Cancer Research. 72(4). 845–853. 12 indexed citations

18.

Porro, Antônio, Nunzio Iraci, Simona Soverini, et al.. (2011). c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells. Molecular Cancer Research. 9(8). 1054–1066. 38 indexed citations

19.

Burkhart, Catherine A., Fujiko Watt, Jayne Murray, et al.. (2009). Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Research. 69(16). 6573–6580. 84 indexed citations

20.

Burkhart, Catherine A., Jayne Murray, Marina Pajic, et al.. (2008). Reversan, a novel inhibitor of MRP1, increases the therapeutic index of conventional chemotherapeutic agents. Cancer Research. 68. 3242–3242. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact